Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Lundbeck Vyepti Japan Migraine Approval

Analysis based on 9 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
15
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval expands Lundbeck's commercial footprint into Japan and supports its first independent launch there, a modest positive for the company's long-term revenue outlook in Asia. Market reaction is likely muted given the small near-term revenue contribution, but it reinforces Lundbeck's brain-health franchise and pipeline credibility.

pharmaceuticals biotechnology healthcare

Lundbeck announced on September 16, 2026 that Japan's Bangladesh — Ministry of Health and Family Welfare granted marketing authorization for Vyepti (eptinezumab) for the prevention of migraine attacks in adults. Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and is administered intravenously. It is the only intravenous CGRP-targeted preventive migraine treatment approved in Japan and is now launched in more than 30 markets worldwide. The Japanese authorization was supported by the global Phase III development program including PROMISE-1, PROMISE-2 and DELIVER, the Phase III SUNRISE trial in a predominantly Asian population with chronic migraine, and the SUNSET long-term extension study in Japanese patients. Eptinezumab was first approved by the U.S. United States — Food and Drug Administration in February 2020 and subsequently received marketing authorization from the International — European Commission in January 2022, with approvals also in South Korea. The approval paves the way for Lundbeck's first launch in Japan as Marketing Authorization holder, enabling the company to operate independently in the Japanese market after 25 years of commitment to brain health in the country. Migraine affects an estimated 8.4 to 11.0 percent of the Japanese population and is estimated to cost the Japanese economy about US$3 billion annually in lost productivity.

priv
Lundbeck receives Japanese marketing authorization for Vyepti, enabling its first independent launch in Japan and expanding its migraine franchise into a new major market.
Importance 95.0 Sentiment 25.0
govactor
Japan's regulator granted the marketing authorization for eptinezumab, enabling patient access to the treatment in Japan.
Importance 70.0 Sentiment 5.0
cnt
Japan gains a new intravenous CGRP-targeted preventive migraine therapy for adults, potentially reducing the estimated US$3 billion annual productivity burden.
Importance 60.0 Sentiment 5.0
govactor
The FDA's 2020 approval of eptinezumab is cited as the first regulatory clearance underpinning the drug's global rollout.
Importance 20.0 Sentiment 0.0
govactor
The International — European Commission's January 2022 marketing authorization is referenced as part of eptinezumab's international approval history.
Importance 20.0 Sentiment 0.0
alliance
The European Union is mentioned as one of the regions where eptinezumab has been approved and launched.
Importance 15.0 Sentiment 0.0
cnt
South Korea is cited as a recent market where eptinezumab received regulatory clearance.
Importance 15.0 Sentiment 0.0
cnt
Denmark is the headquarters country of Lundbeck, the company receiving the Japanese approval.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.